Open AccessThe metabolic effects of lopinavir/ritonavir in HIV-negative men
Author(s) -
Grace A. Lee,
Tara Seneviratne,
Mustafa A. Noor,
Joan C. Lo,
Jean-Marc Schwarz,
Francesca Aweeka,
Kathleen Mulligan,
Morris Schambelan,
Carl Grünfeld
Publication year - 2004
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/00002030-200403050-00008
Subject(s) - lopinavir , lopinavir/ritonavir , ritonavir , medicine , endocrinology , insulin , triglyceride , insulin resistance , cholesterol , human immunodeficiency virus (hiv) , viral load , immunology , disease , covid-19 , antiretroviral therapy , infectious disease (medical specialty)
Therapy with HIV protease inhibitors (PI) has been shown to worsen glucose and lipid metabolism, but whether these changes are caused by direct drug effects, changes in disease status, or body composition is unclear. Therefore, we tested the effects of the PI combination lopinavir and ritonavir on glucose and lipid metabolism in HIV-negative subjects.